Literature DB >> 29358664

Delayed onset of autoreactive antibody production and M2-skewed macrophages contribute to improved survival of TACI deficient MRL-Fas/Lpr mouse.

Lunhua Liu1, Windy Rose Allman1, Adam Steven Coleman1, Kazuyo Takeda2, Tsai-Lien Lin3, Mustafa Akkoyunlu4.   

Abstract

Anti-B cell activating factor belonging to TNF-family (BAFF) antibody therapy is indicated for the treatment of patients with active systemic lupus erythematosus (SLE). We hypothesized that the BAFF receptor, transmembrane activator and calcium-modulator and cyclophilin interactor (TACI) may be responsible for the generation of antibody secreting plasma cells in SLE. To test this hypothesis, we generated TACI deficient MRL-Fas/Lpr (LPR-TACI-/-) mouse. TACI deficiency resulted in improved survival of MRL-Fas/Lpr mice and delayed production of anti-dsDNA and anti-SAM/RNP antibodies. There was also a delay in the onset of proteinuria and the accumulation of IgG and inflammatory macrophages (Mϕs) in the glomeruli of young LPR-TACI-/- mice compared to wild-type mice. Underscoring the role of TACI in influencing Mϕ phenotype, the transfer of Mϕs from 12-week-old LPR-TACI-/- mice to age-matched sick wild-type animals led to a decrease in proteinuria and improvement in kidney pathology. The fact that, in LPR-TACI-/- mouse a more pronounced delay was in IgM and IgG3 autoreactive antibody isotypes and the kinetics of follicular helper T (Tfh) cell-development was comparable between the littermates suggest a role for TACI in T cell-independent autoantibody production in MRL-Fas/Lpr mouse prior to the onset of T cell-dependent antibody production.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29358664      PMCID: PMC5778001          DOI: 10.1038/s41598-018-19827-8

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  71 in total

1.  IgG3 production in MRL/lpr mice is responsible for development of lupus nephritis.

Authors:  S Takahashi; M Nose; J Sasaki; T Yamamoto; M Kyogoku
Journal:  J Immunol       Date:  1991-07-15       Impact factor: 5.422

2.  Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients.

Authors:  L D Zhao; Y Li; M F Smith; J S Wang; W Zhang; F L Tang; X P Tian; H Y Wang; F C Zhang; D N Ba; W He; X Zhang
Journal:  Lupus       Date:  2010-11       Impact factor: 2.911

3.  OX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper Response.

Authors:  Clément Jacquemin; Nathalie Schmitt; Cécile Contin-Bordes; Yang Liu; Priya Narayanan; Julien Seneschal; Typhanie Maurouard; David Dougall; Emily Spence Davizon; Hélène Dumortier; Isabelle Douchet; Loïc Raffray; Christophe Richez; Estibaliz Lazaro; Pierre Duffau; Marie-Elise Truchetet; Liliane Khoryati; Patrick Mercié; Lionel Couzi; Pierre Merville; Thierry Schaeverbeke; Jean-François Viallard; Jean-Luc Pellegrin; Jean-François Moreau; Sylviane Muller; Sandy Zurawski; Robert L Coffman; Virginia Pascual; Hideki Ueno; Patrick Blanco
Journal:  Immunity       Date:  2015-06-09       Impact factor: 31.745

4.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Authors:  Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

5.  Murine monoclonal anti-DNA antibodies penetrate cells, bind to nuclei, and induce glomerular proliferation and proteinuria in vivo.

Authors:  D Vlahakos; M H Foster; A A Ucci; K J Barrett; S K Datta; M P Madaio
Journal:  J Am Soc Nephrol       Date:  1992-02       Impact factor: 10.121

6.  Raised serum APRIL levels in patients with systemic lupus erythematosus.

Authors:  T Koyama; H Tsukamoto; Y Miyagi; D Himeji; J Otsuka; H Miyagawa; M Harada; T Horiuchi
Journal:  Ann Rheum Dis       Date:  2004-12-02       Impact factor: 19.103

7.  Increased serum APRIL differentially correlates with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients.

Authors:  Ghada Boghdadi; Enass A Elewa
Journal:  Rheumatol Int       Date:  2014-04-21       Impact factor: 2.631

Review 8.  What is damaging the kidney in lupus nephritis?

Authors:  Anne Davidson
Journal:  Nat Rev Rheumatol       Date:  2015-11-19       Impact factor: 20.543

9.  IgG3 deficiency extends lifespan and attenuates progression of glomerulonephritis in MRL/lpr mice.

Authors:  Neil S Greenspan; Myro A Lu; Jacob W Shipley; Xuedong Ding; Qing Li; Dilara Sultana; Maria Kollaros; John R Schreiber; Pingfu Fu; Chaim Putterman; Steven N Emancipator
Journal:  Biol Direct       Date:  2012-01-16       Impact factor: 4.540

10.  BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth.

Authors:  P Schneider; F MacKay; V Steiner; K Hofmann; J L Bodmer; N Holler; C Ambrose; P Lawton; S Bixler; H Acha-Orbea; D Valmori; P Romero; C Werner-Favre; R H Zubler; J L Browning; J Tschopp
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

View more
  8 in total

1.  PAM3 supports the generation of M2-like macrophages from lupus patient monocytes and improves disease outcome in murine lupus.

Authors:  Begum Horuluoglu; Defne Bayik; Neslihan Kayraklioglu; Emilie Goguet; Mariana J Kaplan; Dennis M Klinman
Journal:  J Autoimmun       Date:  2019-01-22       Impact factor: 7.094

Review 2.  Leptin: an unappreciated key player in SLE.

Authors:  Qihang Yuan; Haifeng Chen; Xia Li; Jing Wei
Journal:  Clin Rheumatol       Date:  2019-11-09       Impact factor: 2.980

3.  Increased Expression of PPAR-γ Modulates Monocytes Into a M2-Like Phenotype in SLE Patients: An Implicative Protective Mechanism and Potential Therapeutic Strategy of Systemic Lupus Erythematosus.

Authors:  Yu Liu; Shuangyan Luo; Yi Zhan; Jiayu Wang; Rui Zhao; Yingjie Li; Jinrong Zeng; Qianjin Lu
Journal:  Front Immunol       Date:  2021-01-19       Impact factor: 7.561

4.  Azithromycin alleviates systemic lupus erythematosus via the promotion of M2 polarisation in lupus mice.

Authors:  Jie Wang; Qian Chen; Zhixiong Zhang; Shangshang Wang; Yilun Wang; Mengmeng Xiang; Jun Liang; Jinhua Xu
Journal:  Cell Death Discov       Date:  2021-04-16

5.  Impaired B Cell Apoptosis Results in Autoimmunity That Is Alleviated by Ablation of Btk.

Authors:  Jacqueline A Wright; Cassandra Bazile; Emily S Clark; Gianluca Carlesso; Justin Boucher; Eden Kleiman; Tamer Mahmoud; Lily I Cheng; Darlah M López-Rodríguez; Anne B Satterthwaite; Norman H Altman; Eric L Greidinger; Wasif N Khan
Journal:  Front Immunol       Date:  2021-08-26       Impact factor: 7.561

Review 6.  Regulating the Polarization of Macrophages: A Promising Approach to Vascular Dermatosis.

Authors:  Huiling Peng; Dehai Xian; Jiexiong Liu; Shihong Pan; Ran Tang; Jianqiao Zhong
Journal:  J Immunol Res       Date:  2020-07-28       Impact factor: 4.818

7.  Azithromycin promotes alternatively activated macrophage phenotype in systematic lupus erythematosus via PI3K/Akt signaling pathway.

Authors:  Jie Wang; Lin Xie; Shangshang Wang; Jinran Lin; Jun Liang; Jinhua Xu
Journal:  Cell Death Dis       Date:  2018-10-22       Impact factor: 8.469

8.  Disease Stage-Specific Pathogenicity of CD138 (Syndecan 1)-Expressing T Cells in Systemic Lupus Erythematosus.

Authors:  Lunhua Liu; Kazuyo Takeda; Mustafa Akkoyunlu
Journal:  Front Immunol       Date:  2020-07-28       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.